Expected adverse events in a mass smallpox vaccination campaign.
about
Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceSafety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Finding and removing highly connected individuals using suboptimal vaccines.Comparison of smallpox outbreak control strategies using a spatial metapopulation model.Inhibition of Poxvirus Gene Expression and Genome Replication by Bisbenzimide DerivativesIntegrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination.Contingency planning for a deliberate release of smallpox in Great Britain--the role of geographical scale and contact structure.The poxvirus A35 protein is an immunoregulatorCan vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient miceManagement of complex regional pain syndrome.Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.Contribution of TAT system translocated PhoX to Campylobacter jejuni phosphate metabolism and resilience to environmental stresses.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switchingDevelopment of the small-molecule antiviral ST-246 as a smallpox therapeutic.Immunomodulator-based enhancement of anti smallpox immune responses.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cellsComparative proteomics of human monkeypox and vaccinia intracellular mature and extracellular enveloped virionsAssessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbitsSafety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeuticsApplication of pharmacogenomics to vaccines.Genetic basis for adverse events after smallpox vaccination.Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes.Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections
P2860
Q24799168-D82EF0CA-6A34-4169-8B3C-DEE41EE8BF9EQ28748570-E7B3064E-01EB-40D5-A21B-F20AC28EECCFQ30151079-46C13CF6-3436-481A-A274-43A263635CEBQ30224717-3A32AD72-9149-48EC-9C23-F43654126958Q30230157-173547C5-647C-4490-836C-DB1E38A8214EQ32174436-2132D53A-1296-41CD-8CA5-3F4CB4914721Q33376970-926F9062-F5DF-41B1-B2A8-7B527E509C8FQ33530946-4B5D7DB1-2D1E-46E3-A44B-AB5AC2E54465Q33558734-22F44714-13CD-40FB-AFB6-68C2DA96A27FQ33614263-D95E5BF4-5EB7-42C9-B928-CAECBA0FB286Q33624420-A3AFAEF5-373E-4364-A9B4-83860CD361EFQ33639966-5FA5DBB8-0160-48FE-B196-3A556903C857Q33788741-2BA80C3A-5011-4D94-8BA9-D671D97F90CBQ33843163-2F1698D0-B388-42DB-ADEC-1A9C1CFE98DBQ34058529-107A7A83-598E-482B-81F4-FBA9EA21413FQ34502253-8F41EAB5-F74D-4BE4-8E84-5C25B243A265Q34810232-69E662B9-21EF-4E54-A559-D01411F56504Q35152092-53BE7BF0-9611-4CC3-A184-7D2FC19C40DBQ35391402-66D87F9E-8CF0-4873-BBCA-4E79A95448A0Q35571248-A033E0A0-E91F-4588-B538-4E94355F6B1CQ35800226-3754509C-22EE-4351-8553-84E7B185FE54Q36172531-56566645-6E35-4D59-AE3D-0F135149225FQ36391900-52FDA8E2-F5AB-43BB-ABB8-DBB2996A51E6Q36827391-8961793D-CA84-439D-8536-98B4E920EEC6Q36839627-58C617F7-B18C-4740-A0C9-B94A92C2A070Q36978610-309D0BB1-C74C-4B65-B322-4C6D0A9DF48EQ37135398-C95CD470-9FDE-4F1C-A9F7-71CAE3E6A8ABQ37191938-494C9D5F-6F7E-410E-AAE6-2685EA32349AQ37293663-4E8BC60C-7D40-4A23-96AC-B77333E110BAQ37351650-AE36A9D0-331E-4E01-87AC-BFC42586096AQ37375372-5E6AC75C-6751-40DB-A72D-C62097404081Q38962075-7D265AB2-1570-4E86-A850-EE1BA11B80E1Q38970262-68C15D1E-912E-4A03-951C-05E30B6DB73BQ39207337-0F42A11A-295D-4C33-BD50-6D2641759BB7Q39613014-A938D7B1-E82D-49DC-B5BE-633FAE62FE68Q40153814-6A96CD77-B1BC-49AA-96B9-D719A081C76BQ40494092-80D58306-D403-4C43-B23B-C4745EAEEDBE
P2860
Expected adverse events in a mass smallpox vaccination campaign.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Expected adverse events in a mass smallpox vaccination campaign.
@en
type
label
Expected adverse events in a mass smallpox vaccination campaign.
@en
prefLabel
Expected adverse events in a mass smallpox vaccination campaign.
@en
P2093
P1476
Expected adverse events in a mass smallpox vaccination campaign.
@en
P2093
Alex R Kemper
Gary L Freed
Matthew M Davis
P577
2002-03-01T00:00:00Z